Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study.
Identifieur interne : 002063 ( Ncbi/Curation ); précédent : 002062; suivant : 002064Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study.
Auteurs : David Devos [France] ; Kathy Dujardin ; Isabelle Poirot ; Caroline Moreau ; Olivier Cottencin ; Pierre Thomas ; Alain Destée [France] ; Regis Bordet ; Luc Defebvre [France]Source :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2008.
English descriptors
- KwdEn :
- Aged, Antidepressive Agents (adverse effects), Antidepressive Agents (therapeutic use), Citalopram (adverse effects), Citalopram (therapeutic use), Depression (drug therapy), Depression (etiology), Desipramine (adverse effects), Desipramine (therapeutic use), Double-Blind Method, Female, Humans, Male, Middle Aged, Parkinson Disease (psychology), Placebos, Prevalence, Psychiatric Status Rating Scales.
- MESH :
- chemical , adverse effects : Antidepressive Agents, Citalopram, Desipramine.
- chemical , therapeutic use : Antidepressive Agents, Citalopram, Desipramine.
- drug therapy : Depression.
- etiology : Depression.
- psychology : Parkinson Disease.
- Aged, Double-Blind Method, Female, Humans, Male, Middle Aged, Placebos, Prevalence, Psychiatric Status Rating Scales.
Abstract
Depression is one of the most common psychiatric disturbances in Parkinson's disease (PD). Recent reviews have highlighted the lack of controlled trials and the ensuing difficulty in formulating recommendations for antidepressant use in PD. We sought to establish whether antidepressants provide real benefits and whether tricyclic and selective serotonin reuptake inhibitor (SSRI) antidepressants differ in their short-term efficacy, because the time to onset of therapeutic benefit remains an important criterion in depression. The short-term efficacy (after 14 and 30 days) of two antidepressants (desipramine, a predominantly noradrenergic reuptake inhibitor tricyclic and citalopram, a SSRI) was assessed in a double-blind, randomized, placebo- controlled study of 48 nondemented PD patients suffering from major depression. After 14 days, desipramine prompted an improvement in the Montgomery Asberg Depression Rating Scale (MADRS) score, compared with citalopram and placebo. Both antidepressants produced significant improvements in the MADRS score after 30 days. Mild adverse events were twice as frequent in the desipramine group as in the other groups. A predominantly noradrenergic tricyclic antidepressant induced a more intense short-term effect on parkinsonian depression than did an SSRI. However, desipramine's lower tolerability may outweigh its slight short-term clinical advantage.
DOI: 10.1002/mds.21966
PubMed: 18311826
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002298
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :002298
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :002372
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :002063
Links to Exploration step
pubmed:18311826Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study.</title><author><name sortKey="Devos, David" sort="Devos, David" uniqKey="Devos D" first="David" last="Devos">David Devos</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital, Lille, France. d-devos@chru-lille.fr</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Neurology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital, Lille</wicri:regionArea><placeName><settlement type="city">Lille</settlement></placeName></affiliation></author><author><name sortKey="Dujardin, Kathy" sort="Dujardin, Kathy" uniqKey="Dujardin K" first="Kathy" last="Dujardin">Kathy Dujardin</name></author><author><name sortKey="Poirot, Isabelle" sort="Poirot, Isabelle" uniqKey="Poirot I" first="Isabelle" last="Poirot">Isabelle Poirot</name></author><author><name sortKey="Moreau, Caroline" sort="Moreau, Caroline" uniqKey="Moreau C" first="Caroline" last="Moreau">Caroline Moreau</name></author><author><name sortKey="Cottencin, Olivier" sort="Cottencin, Olivier" uniqKey="Cottencin O" first="Olivier" last="Cottencin">Olivier Cottencin</name></author><author><name sortKey="Thomas, Pierre" sort="Thomas, Pierre" uniqKey="Thomas P" first="Pierre" last="Thomas">Pierre Thomas</name></author><author><name sortKey="Destee, Alain" sort="Destee, Alain" uniqKey="Destee A" first="Alain" last="Destée">Alain Destée</name><affiliation><country>France</country><placeName><settlement type="city">Lille</settlement><region type="region" nuts="2">Nord-Pas-de-Calais</region></placeName><orgName type="university" n="3">Université Lille 2</orgName><orgName type="institution" wicri:auto="newGroup">Université Lille Nord de France</orgName></affiliation></author><author><name sortKey="Bordet, Regis" sort="Bordet, Regis" uniqKey="Bordet R" first="Regis" last="Bordet">Regis Bordet</name></author><author><name sortKey="Defebvre, Luc" sort="Defebvre, Luc" uniqKey="Defebvre L" first="Luc" last="Defebvre">Luc Defebvre</name><affiliation><country>France</country><placeName><settlement type="city">Lille</settlement><region type="region" nuts="2">Nord-Pas-de-Calais</region></placeName><orgName type="university" n="3">Université Lille 2</orgName><orgName type="institution" wicri:auto="newGroup">Université Lille Nord de France</orgName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2008">2008</date><idno type="doi">10.1002/mds.21966</idno><idno type="RBID">pubmed:18311826</idno><idno type="pmid">18311826</idno><idno type="wicri:Area/PubMed/Corpus">002298</idno><idno type="wicri:Area/PubMed/Curation">002298</idno><idno type="wicri:Area/PubMed/Checkpoint">002372</idno><idno type="wicri:Area/Ncbi/Merge">002063</idno><idno type="wicri:Area/Ncbi/Curation">002063</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study.</title><author><name sortKey="Devos, David" sort="Devos, David" uniqKey="Devos D" first="David" last="Devos">David Devos</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital, Lille, France. d-devos@chru-lille.fr</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Neurology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital, Lille</wicri:regionArea><placeName><settlement type="city">Lille</settlement></placeName></affiliation></author><author><name sortKey="Dujardin, Kathy" sort="Dujardin, Kathy" uniqKey="Dujardin K" first="Kathy" last="Dujardin">Kathy Dujardin</name></author><author><name sortKey="Poirot, Isabelle" sort="Poirot, Isabelle" uniqKey="Poirot I" first="Isabelle" last="Poirot">Isabelle Poirot</name></author><author><name sortKey="Moreau, Caroline" sort="Moreau, Caroline" uniqKey="Moreau C" first="Caroline" last="Moreau">Caroline Moreau</name></author><author><name sortKey="Cottencin, Olivier" sort="Cottencin, Olivier" uniqKey="Cottencin O" first="Olivier" last="Cottencin">Olivier Cottencin</name></author><author><name sortKey="Thomas, Pierre" sort="Thomas, Pierre" uniqKey="Thomas P" first="Pierre" last="Thomas">Pierre Thomas</name></author><author><name sortKey="Destee, Alain" sort="Destee, Alain" uniqKey="Destee A" first="Alain" last="Destée">Alain Destée</name><affiliation><country>France</country><placeName><settlement type="city">Lille</settlement><region type="region" nuts="2">Nord-Pas-de-Calais</region></placeName><orgName type="university" n="3">Université Lille 2</orgName><orgName type="institution" wicri:auto="newGroup">Université Lille Nord de France</orgName></affiliation></author><author><name sortKey="Bordet, Regis" sort="Bordet, Regis" uniqKey="Bordet R" first="Regis" last="Bordet">Regis Bordet</name></author><author><name sortKey="Defebvre, Luc" sort="Defebvre, Luc" uniqKey="Defebvre L" first="Luc" last="Defebvre">Luc Defebvre</name><affiliation><country>France</country><placeName><settlement type="city">Lille</settlement><region type="region" nuts="2">Nord-Pas-de-Calais</region></placeName><orgName type="university" n="3">Université Lille 2</orgName><orgName type="institution" wicri:auto="newGroup">Université Lille Nord de France</orgName></affiliation></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2008" type="published">2008</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Antidepressive Agents (adverse effects)</term><term>Antidepressive Agents (therapeutic use)</term><term>Citalopram (adverse effects)</term><term>Citalopram (therapeutic use)</term><term>Depression (drug therapy)</term><term>Depression (etiology)</term><term>Desipramine (adverse effects)</term><term>Desipramine (therapeutic use)</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease (psychology)</term><term>Placebos</term><term>Prevalence</term><term>Psychiatric Status Rating Scales</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antidepressive Agents</term><term>Citalopram</term><term>Desipramine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antidepressive Agents</term><term>Citalopram</term><term>Desipramine</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Depression</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Depression</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Placebos</term><term>Prevalence</term><term>Psychiatric Status Rating Scales</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Depression is one of the most common psychiatric disturbances in Parkinson's disease (PD). Recent reviews have highlighted the lack of controlled trials and the ensuing difficulty in formulating recommendations for antidepressant use in PD. We sought to establish whether antidepressants provide real benefits and whether tricyclic and selective serotonin reuptake inhibitor (SSRI) antidepressants differ in their short-term efficacy, because the time to onset of therapeutic benefit remains an important criterion in depression. The short-term efficacy (after 14 and 30 days) of two antidepressants (desipramine, a predominantly noradrenergic reuptake inhibitor tricyclic and citalopram, a SSRI) was assessed in a double-blind, randomized, placebo- controlled study of 48 nondemented PD patients suffering from major depression. After 14 days, desipramine prompted an improvement in the Montgomery Asberg Depression Rating Scale (MADRS) score, compared with citalopram and placebo. Both antidepressants produced significant improvements in the MADRS score after 30 days. Mild adverse events were twice as frequent in the desipramine group as in the other groups. A predominantly noradrenergic tricyclic antidepressant induced a more intense short-term effect on parkinsonian depression than did an SSRI. However, desipramine's lower tolerability may outweigh its slight short-term clinical advantage.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002063 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 002063 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Ncbi
|étape= Curation
|type= RBID
|clé= pubmed:18311826
|texte= Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:18311826" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |